Program
HLX15
Also written as “HLX15-SC-Rd” and “HLX15-IV”.
Its studies are mostly in Multiple Myeloma, led by Fosun Pharma.
Furthest: phase 3, since Mar 10, 20253 company-led studies, 2 open or runningNext primary completion: May 25, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 32 open or running | phase 3since Mar 10, 2025 | Dec 21, 2022 | May 25, 2027phase 1 · NCT07477587 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05679258 · 172 enrolled · China
- Mar 10, 2025Phase 3 study in Newly Diagnosed Multiple MyelomaNCT06895512 · 386 planned · China
- Feb 27, 2026Phase 1 study in Multiple MyelomaNCT07477587 · 258 planned · United States, Australia, China and more
Ahead
- May 25, 2027Primary completion: phase 1 study in Multiple MyelomaNCT07477587
- Jul 2027Primary completion: phase 3 study in Newly Diagnosed Multiple MyelomaNCT06895512
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07477587Multiple Myeloma · United States, Australia, China and more | 1 | Recruiting | May 25, 2027 | 258 |
| NCT06895512Newly Diagnosed Multiple Myeloma · China | 3 | Not yet recruiting | Jul 2027 | 386 |
| NCT05679258Multiple Myeloma · China | 1 | Completed | Mar 16, 2024 | 172 |
How it is read
Names in the registry
- “HLX15-SC-Rd”, 1 entry
- “HLX15-IV”, 1 entry
- “HLX15”, 1 entry
Codes read as this program: HLX15.
Conditions, from the studies’ own filings
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.